Home/Healthcare & Aging Society/Nihon Kohden Corporation

Nihon Kohden Corporation

6849.TMEDIUM

Core · Weight: 8%· Data as of 2026-05-25

¥1,442.5-0.14%

6-month daily

Investment Thesis

Mean-reversion thesis: SLOWER than expected. FY2026: revenue +4.3% to ¥235.1B, but operating income FELL 9.5% to ¥18.7B (OpMar 7.97%, below target). Ordinary profit +10.7% to ¥22.5B on non-operating income. Q4 FY2026 operating profit ¥10.6B (+55.3% YoY) — strong exit momentum. FY2027 guidance: operating profit +25.4% to ¥23.5B (implied OpMar ~10%) — recovery underway. BEACON 2030 15% target unachievable by FY2027 (realistic: 10-12% by FY2027). US expansion: Life Scope G7 monitor launched + Software Central Station FDA-cleared (June 2025). Stock at 52-week low of ¥1,408 on May 15 (just 10 days ago), bounced to ¥1,720 on FY2027 guidance.

Risk

1) BEACON 2030 Phase II target of 15% OpMar by FY2027 now clearly unachievable — sets up credibility risk if FY2028+ targets also missed. 2) PE re-rated from 13.9x to 20.3x without EPS growth — thesis requires FY2027 margin recovery to justify valuation. 3) Domestic revenue slightly declined despite aging tailwinds — competitive or procurement timing risk. 4) R&D and wage inflation headwinds persisting (cited in FY2026 miss).

Monitoring Trigger

If FY2027 Q1 (Oct 2026) OpMar exceeds 9.5%, ADD to 10% (recovery confirmed). If FY2027 full-year OpMar reaches 10%+, re-rate to HIGH conviction. If OpMar stays below 8% for FY2027 H1, TRIM to 5% (structural margin floor, not trough). Watch US revenue contribution — needs to reach 20%+ to diversify domestic risk.

Key Dates

2026-08earningsFY2027 Q1 results — first key test of BEACON recovery. Watch OpMar vs 9.5% threshold.

2027catalystBEACON 2030 Phase III entry — new 5-year targets likely to reset ambitions

2027-05earningsFY2027 full-year results — critical: does OpMar reach 10%+ as guided?

Update History

2026-05-04exploreHOLD

View report →

Added supply_chain entries (was empty). 3 entries added: Japan hospital duopoly, eICU North America, competitor mapping.

supply_chain:[] (empty)3 entries added

2026-05-25evolveHOLD

View report →

FY2026 post-results: revenue +4.3%, OpMar fell to 7.97% (below 9.2% expectation). FY2027 guidance +25.4% OP recovery. 52-week low ¥1,408 (May 15) — bounced to ¥1,720. US expansion: Life Scope G7 launch, FDA 510(k) software CNS cleared. BEACON 15% target unachievable FY2027.

pe:13.920.3forward_pe:N/A18.9pb:1.441.35op_margin:9.2%7.97%div_yield:2.1%1.92%market_cap:N/A¥285Bkey_dates:[]3 dates addedsupply_chain:3 entries3 entries — US expansion UPGRADED with Life Scope G7 + FDA clearance

Key Metrics

20.3

18.9

Fwd PE

1.35

P/B

7.1%

ROE

7.97%

Op Margin

15.0%

D/E

1.92%

Div Yield

N/A

FCF

¥285B

Mkt Cap

Supply Chain Evidence

Evidence	Customer	Product	Detail
confirmed	Japanese hospitals and clinics (nationwide)	Patient monitoring systems, ECG, defibrillators	Duopoly with Fukuda Denshi (6960.T). Japan patient monitoring market ¥400B growing at 7.3% CAGR to 2033. Domestic revenue slightly declined in FY2026 despite aging tailwinds.[source](2026-05)
confirmed	North American ICU facilities (US expansion)	Life Scope G7 patient monitor + Software Central Station (FDA 510(k) K242750)	NEW: Life Scope G7 US launch (2026). FDA 510(k) clearance for software-only central monitoring station (June 2025, K242750). BEACON 2030 phase targets 20%+ North America revenue.[source](2025-06)
confirmed		Patient monitoring, ECG, defibrillators	Domestic duopoly with Fukuda Denshi; Philips/GE are global peers in ICU monitoring.[source](2026-05)

Sources & References

↗↗

Peer Comparison

Company	PE	Fwd PE	ROE	Op Margin	FCF
Nihon Kohden Corporation	20.3	18.9	7.1%	7.97%	N/A
M3, Inc.	19.4	17.9	12.2%	20.9%	N/A
Fukuda Denshi Co., Ltd.	15.87	15.66	8.6%	18.0%	+¥21B
JMDC Inc.	35.85	29.06	7.8%	22.3%	+¥9B
PHC Holdings Corporation	38.5	10.71	0.6%	6.2%	+¥32B
Sysmex Corporation	22.5	N/A	N/A	~20% (est. from EBITDA 25.3%)	N/A
Olympus Corporation	22.98	N/A	N/A	18.9% (adj FY2025)	+¥109B (adj FY2025)